Status | Study |
Enrolling by invitation |
Study Name: Dual Algorithm Post Market Clinical Study Condition: HTLV-I Infections HTLV-II Infections Human T-lymphotropic Date: 2017-05-05 Interventions: Diagnostic Test: MP Diagnostics HTLV Blot 2.4 HTLV I/II Confirmation and Differentiation |
Recruiting |
Study Name: Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM) Condition: HAM Date: 2016-11-03 Interventions: Biological: NK cells single in |
Not yet recruiting |
Study Name: Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection Condition: HTLV-I Infections Tropical Spastic Paraparesis Date: 2015-11-16 Interventions: Drug: "Raltegravir" and "Zidovudine" Through measure of pro-viral load and clinical |
Recruiting |
Study Name: Raltegravir for HAM/TSP Condition: HTLV-I Infection Date: 2013-05-21 Interventions: Drug: Raltegravir |
Enrolling by invitation |
Study Name: Urological Physical Therapy in HTLV-1 With Urinary Symptoms Condition: Tropical Spastic Paraparesis HTLV-1 Date: 2012-07-25 Interventions: Procedure: Urological physical therapy Individual patient attending with one hour duration beginning wit |
Completed |
Study Name: Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Condition: HTLV-1 Tropical Spastic Paraparesis Date: 2011-11-11 Interventions: Drug: Pentoxifylline Pentoxify |
Enrolling by invitation |
Study Name: Evaluation of the MP Diagnostics HTLV Blot 2.4 Condition: HTLV-I Infections HTLV-II Infections Human T-lymphotropic Date: 2011-10-31 Interventions: Other: CDPHL Algorithm Supplemental testing algorithm performed by the CDPHL. |
Completed |
Study Name: Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Condition: HTLV-I-Associated Myelopathy Date: 2011-04-25 Interventions: Drug: Tamibarotene Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg da |
Terminated |
Study Name: The HAM Infliximab Study Condition: HTLV-I-associated Myelopathy Date: 2009-01-14 Interventions: Drug: Infliximab Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks unti |
Completed |
Study Name: Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Condition: HTLV I Associated Myelopathy Date: 2008-10-15 Interventions: Drug: ciclosporin Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to |